CytomX Therapeutics
CTMX
75 hedge funds and large institutions have $53.7M invested in CytomX Therapeutics in 2023 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 12 increasing their positions, 36 reducing their positions, and 13 closing their positions.
86% more call options, than puts
Call options by funds: $104K | Put options by funds: $56K
0.78% less ownership
Funds ownership: 54.45% → 53.67% (-0.78%)
6% less capital invested
Capital invested by funds: $57.2M → $53.7M (-$3.56M)
7% less funds holding
Funds holding: 81 → 75 (-6)
46% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 13
67% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 36
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$5.84M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$2.78M |
| 3 |
BCM
Bronte Capital Management
Bondi Junction,
Australia
|
+$2.07M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$1.65M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$756K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$3.85M |
| 2 |
Millennium Management
New York
|
-$1.71M |
| 3 |
Renaissance Technologies
New York
|
-$1.11M |
| 4 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
-$1.02M |
| 5 |
OMC
Oasis Management Company
Grand Cayman,
Cayman Islands
|
-$865K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
RCMNY
76
Rubric Capital Management (New York)
New York
| – | -$3.85M | -2,406,449 | Closed |
|
|
PIM
77
Platinum Investment Management
Sydney Australia 2000,
Australia
| – | -$1.02M | -635,798 | Closed |
|
|
OMC
78
Oasis Management Company
Grand Cayman,
Cayman Islands
| – | -$865K | -540,541 | Closed |
|
|
CM
79
CM Management
Gulf Breeze,
Florida
| – | -$120K | -75,000 | Closed |
|
80
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$120K | -69,600 | Closed |
|
|
AGM
81
Alpine Global Management
New York
| – | -$76K | -47,723 | Closed |
|
82
Balyasny Asset Management
Chicago,
Illinois
| – | -$55.7K | -34,800 | Closed |
|
83
Verition Fund Management
Greenwich,
Connecticut
| – | -$43.7K | -27,296 | Closed |
|
84
Belvedere Trading
Chicago,
Illinois
| – | -$38.7K | -24,200 | Closed |
|
85
Mackenzie Financial
Toronto Ontario,
Ontario, Canada
| – | -$25K | -15,639 | Closed |
|
|
EGM
86
Engineers Gate Manager
New York
| – | -$16.2K | -10,135 | Closed |
|
87
Rockefeller Capital Management
New York
| – | -$2K | -1,864 | Closed |
|
CTMX Hedge Fund Activity: Q1 2023 in Review
75 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q1 2023, worth a combined $53.7M — down 6.2% from $57.2M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of CTMX and 7 opened new positions — a net loss of 6 holders — while 36 trimmed existing stakes and 12 added.
The largest buyer was Tang Capital Management, adding an estimated $5.84M. The largest seller was Rubric Capital Management (New York), exiting entirely with an estimated $3.85M sold.
- 75 institutional investors held CytomX Therapeutics (CTMX) as of Q1 2023, down from 81 in Q4 2022.
- Funds reported $53.7M of CytomX Therapeutics stock for Q1 2023, down 6.2% quarter-over-quarter.
- 7 funds opened new CytomX Therapeutics positions in Q1 2023 and 13 closed out, a net change of -6 holders.
- The largest CytomX Therapeutics buyer in Q1 2023 was Tang Capital Management, an estimated $5.84M added.
- The largest CytomX Therapeutics seller in Q1 2023 was Rubric Capital Management (New York), an estimated $3.85M sold.
Based on aggregated 13F filings for Q1 2023.